Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MedSurg

How Is Solventum's Stock Performance Compared to Other Health Care Equipment Stocks?

Solventum has outperformed relative to its healthcare equipment peers over the past year, but Wall Street analysts maintain a skeptical view on the stock’s outlook.

Solventum Stock Outlook: Is Wall Street Bullish or Bearish?

Solventum Stock Outlook: Is Wall Street Bullish or Bearish?

Solventum has outperformed the broader market over the past year, yet analysts remain cautious about the stock’s prospects.

Is Wall Street Bullish or Bearish on Solventum Stock?

Is Wall Street Bullish or Bearish on Solventum Stock?

Due to Solventum’s underperformance relative to the broader S&P 500 Index over the past six months, Wall Street analysts remain cautious about the stock’s prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Solventum's Quarterly Earnings Preview: What You Need to Know

Solventum is scheduled to report its third-quarter results next month.

Stryker - Growth Through Aggressive M&A

Summary Stryker Corporation (SYK) shows strong technical buy signals, with a 6.09% gain since 8/21, and consistent price appreciation across key moving averages. The company operates in MedSurg, Neurotechnology, Orthopaedics, and Spine segments, offering a wide range of medical devices and technologies. Analysts provide mixed ratings, with price targets ranging...

Boston Scientific Stock: Is Wall Street Bullish or Bearish?

Boston Scientific has significantly outperformed the broader market YTD, and Wall Street analysts are still bullish about the stock’s prospects.

6 Stocks To Buy That Are Near 52-Week Lows

Weakness in the S&P 500 has made life unpleasant for investors so far in 2022, but it has also created buying opportunities in a handful of high-quality stocks. Long-term investors looking to buy the dip can find plenty of stocks to buy that are at or near their lowest prices…

inkl

Read news from The Economist, FT, and more,
with one subscription

Boston Scientific Jumps On Upbeat Q2, FY22 Guidance

Boston Scientific Jumps On Upbeat Q2, FY22 Guidance

Boston Scientific Corp (NYSE:BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of approximately 5% - 8%. The Company achieved…

Organisations

Bank of America

Boston Scientific

Stryker Corporation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play